echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > LDE: In the DAPA-CKD trial, proteinuria and eGFR slope are used to predict treatment response

    LDE: In the DAPA-CKD trial, proteinuria and eGFR slope are used to predict treatment response

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dapagliflozin and the Prevention of Adverse Outcome of Chronic Kidney Disease (DAPA-CKD) trial is a landmark study.


    Established SGLT2 inhibitors as a new standard for the treatment of patients with type 2 diabetes and chronic kidney disease

    The main result of dapagliflozin (estimated glomerular filtration rate [eGFR] decreased by 50%, renal failure, or death from kidney disease or cardiovascular disease) was positive (hazard ratio 0.


    In the journal "The Lancet Diabetes and Endocrinology", two articles conducted a preliminary analysis of proteinuria and eGFR over time


    Dapagliflozin reduced the proteinuria of participants with chronic kidney disease, and the reduction was greater in patients with type 2 diabetes, high HbA1c or diabetic nephropathy.


    Intensive treatment

    Original source:

    Tuttle KR, Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD tria l.


    Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD tria

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.